Aurinia Pharmaceuticals Inc Stock Earnings Reports
Aurinia Pharmaceuticals Earnings Calls
Release date | Feb 20, 2025 |
EPS estimate | $0.0400 |
EPS actual | - |
Revenue estimate | 59.945M |
Revenue actual | - |
Expected change | +/- 9.85% |
Release date | Nov 07, 2024 |
EPS estimate | $0.0150 |
EPS actual | $0.100 |
EPS Surprise | 566.67% |
Revenue estimate | 65.06M |
Revenue actual | 67.771M |
Revenue Surprise | 4.17% |
Release date | Aug 01, 2024 |
EPS estimate | $0.0167 |
EPS actual | $0.0200 |
EPS Surprise | 20.05% |
Revenue estimate | 55.05M |
Revenue actual | 57.192M |
Revenue Surprise | 3.89% |
Release date | May 02, 2024 |
EPS estimate | -$0.170 |
EPS actual | -$0.0300 |
EPS Surprise | 82.35% |
Revenue estimate | 47.45M |
Revenue actual | 50.303M |
Revenue Surprise | 6.01% |
Last 4 Quarters for Aurinia Pharmaceuticals
Below you can see how AUPH performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Release date | May 02, 2024 |
Fiscal end date | Mar 31, 2024 |
Price on release | $5.17 |
EPS estimate | -$0.170 |
EPS actual | -$0.0300 |
EPS surprise | 82.35% |
Date | Price |
---|---|
Apr 26, 2024 | $4.91 |
Apr 29, 2024 | $5.01 |
Apr 30, 2024 | $5.09 |
May 01, 2024 | $5.20 |
May 02, 2024 | $5.17 |
May 03, 2024 | $5.10 |
May 06, 2024 | $5.16 |
May 07, 2024 | $5.12 |
May 08, 2024 | $5.15 |
4 days before | 5.30% |
4 days after | -0.387% |
On release day | -1.35% |
Change in period | 4.89% |
Release date | Aug 01, 2024 |
Fiscal end date | Jun 30, 2024 |
Price on release | $5.61 |
EPS estimate | $0.0167 |
EPS actual | $0.0200 |
EPS surprise | 20.05% |
Date | Price |
---|---|
Jul 26, 2024 | $5.68 |
Jul 29, 2024 | $5.68 |
Jul 30, 2024 | $5.62 |
Jul 31, 2024 | $5.88 |
Aug 01, 2024 | $5.61 |
Aug 02, 2024 | $5.50 |
Aug 05, 2024 | $5.37 |
Aug 06, 2024 | $5.62 |
Aug 07, 2024 | $5.32 |
4 days before | -1.23% |
4 days after | -5.17% |
On release day | -1.96% |
Change in period | -6.34% |
Release date | Nov 07, 2024 |
Fiscal end date | Sep 30, 2024 |
Price on release | $8.34 |
EPS estimate | $0.0150 |
EPS actual | $0.100 |
EPS surprise | 566.67% |
Date | Price |
---|---|
Nov 01, 2024 | $7.32 |
Nov 04, 2024 | $7.21 |
Nov 05, 2024 | $7.32 |
Nov 06, 2024 | $7.52 |
Nov 07, 2024 | $8.34 |
Nov 08, 2024 | $8.32 |
Nov 11, 2024 | $8.49 |
Nov 12, 2024 | $8.38 |
Nov 13, 2024 | $8.28 |
4 days before | 13.93% |
4 days after | -0.719% |
On release day | -0.240% |
Change in period | 13.11% |
Release date | Feb 20, 2025 |
Fiscal end date | Dec 30, 2024 |
Price on release | - |
EPS estimate | $0.0400 |
EPS actual | - |
Date | Price |
---|---|
Feb 06, 2025 | $8.09 |
Feb 07, 2025 | $8.01 |
Feb 10, 2025 | $7.97 |
Feb 11, 2025 | $7.61 |
Feb 12, 2025 | $7.81 |
Aurinia Pharmaceuticals Earnings Call Transcript Summary of Q3 2024
- Net Product Revenue: Rose to $55.5 million in Q3 2024, representing a 36% increase compared to $40.8 million in Q3 2023.
- Year-to-Date Performance: First 9 months of 2024 net revenue reached $175.3 million, up 34% from $130.4 million in the first 9 months of 2023, with net product revenue at $158.6 million.
- Cash Flow: Generated approximately $17 million from operations in Q3 2024. As of September 30, 2024, the company had $348.7 million in cash and equivalents.
Commercial Performance:
- Prescriber and Patient Metrics: Added 364 prescriber-facing accounts (PSFs) and 146 new patient starts, totaling 510 new engagements. Overall, 2,422 patients are now on LUPKYNIS therapy, a 25% increase year-over-year.
- Guidance Reaffirmation: The company maintains its product revenue guidance for 2024 at $210 million to $220 million.
Clinical Development:
- Phase I Study Announcement: The first participant in the Phase I study of AUR200, a BAFF/APRIL dual antagonist, has been dosed, with initial results anticipated in 2025.
- Regulatory Developments: LUPKYNIS received approval from Japanese authorities, triggering a $10 million milestone payment.
Operational Restructuring:
- Workforce Reduction: Approximately 45% of the workforce will be cut to enhance operational efficiency and focus on LUPKYNIS and AUR200 development. This is expected to yield annual cost savings of over $40 million.
- Strategic Focus: The restructuring aims to sharpen commercial and R&D efforts, streamline operations, and strengthen the company's financial position for future growth.
Guidance on Future Developments:
- Aurinia will focus on the ongoing development of AUR200 and expects to present pharmacokinetic profiles and relevant biomarker data from upcoming clinical trials.
- The company plans to provide insights from the ENLIGHT-LN registry concerning real-world treatment patterns, particularly in diverse patient populations, to understand how LUPKYNIS is being utilized.
Conclusion:
Aurinia Pharmaceuticals showed promising growth in Q3 2024, both in terms of revenue and patient metrics, and is strategically positioned for continued expansion following a significant operational restructuring. The company remains optimistic about the commercial viability of LUPKYNIS and the advancement of AUR200 into clinical testing. Investors should monitor the impact of these changes and upcoming data releases as the company transitions into 2025.